UW joins drug trial aimed at preventing major COVID-19 killer: Haywire immune response

UW announced Wednesday that it has joined the Phase III Clinical Trial of a drug known as ruxolitinib, becoming the 32nd site to begin recruiting patients. The drug is a government-approved medication given to bone marrow transplant recipients who are in danger of suffering a cytokine storm. MilwoukeeJournal Centinel